The NRG Oncology Podcast

Episodios

• 
  NRG-HN009 p16-Negative Results at ASTRO 2026 29.09.2026 13m

  We discuss the reported results of the NRG-HN009 p16-negative cohort presented at the ASTRO Annual Meeting Late-Breaking Abstract Session.
• 
  NRG-CC009 and the MAVERICK Study at ASTRO 2026 28.09.2026 21m

  We discuss both the NRG-CC009 study results presented during the 2026 ASTRO Annual Meeting Plenary Session and the MAVERICK study results presented during the Clinical Trials Session.
• 
  NRG-GI003 Results in the ASTRO 2026 Plenary 28.09.2026 14m

  We discuss the NRG-GI003 results presented during the 2026 ASTRO Annual Meeting Plenary Session.
• 
  The SPPORT Study Analysis Results at ASTRO 2026 27.09.2026 11m

  We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.
• 
  The NRG-GY036 Trial for Ovarian Cancer Month 04.09.2026 23m

  For the 2026 Ovarian Cancer Month & Gynecologic Cancer Month, we discuss the currently enrolling NRG-GY036 clinical trial comparing 1 vs. 2 years of maintenance olaparib (with or without bevacizumab) for patients with advanced ovarian cancer with Dr. Liu.
• 
  NRG-HN016: The "CONCISE" Study for Locoregionally Advanced Head and Neck Cancer Patients that are Unable to Take Cisplatin 13.08.2026 17m

  Our co-hosts interview the PI of the active NRG-HN016 (CONCISE) trial, Dr. Loren Mell. The CONCISE study is a randomized phase III trial comparing radiation therapy (RT) plus carboplatin/paclitaxel vs. RT plus cetuximab for patients with locoregionally advanced head and neck cancer who have a contraindication to cisplatin. CONCISE is the first trial comparing the two most commonly used regimens for this population, and the first “pragmatic” trial for solid tumors to be conducted by NRG Oncology.
• 
  NRG-GU015, the "ARCHER" Study for Muscle Invasive Bladder Cancer 30.07.2026 28m

  Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. They also discuss the importance of multidisciplinary care, patient-centered decision-making, and how innovations in radiation therapy and systemic treatments are shaping the future of bladder cancer care. Whether you're a clinician, researcher, or simply interested in advances in oncology, this episode offers valuable insights into a trial designed to improve both outcomes and quality of life for patients.
• 
  NRG2026 and Glioblastoma Awareness Day Special 15.07.2026 38m

  For Glioblastoma Awareness Day we discuss the NRG-CC017 study of TMPRT + Temozolomide for glioblastoma with PI, Dr. Huang. We also discuss the challenges faced by larger institutions with Dr. Abraham.
• 
  Uterine Cancer Awareness Month 2026 23.06.2026 49m

  This special Uterine Cancer Month episode includes three different perspectives in Uterine Cancer research. First we interview uterine and ovarian cancer survivor, NRG PAC Member, and Uterine Corpus Subcommittee Patient Advocate, Anna Wilson. Second we look at the recently activated NRG-GY035 clinical study with PI Dr. Amanda Fader. Lastly we discuss uterine cancer research within NRG with Gynecologic Cancer Committee Chair, Dr. Carol Aghajanian.
• 
  Prostate Cancer Analysis and Translational Science from ASCO 2026 30.05.2026 29m

  In this episode, we discuss the results of the combined analysis of the prostate cancer studies RTOG 9202, 9413, 9902, and 0521 as well as learn more about translational science at NRG.
• 
  NRG-GY018 Mature Results from ASCO 2026 29.05.2026 18m

  Our Podcast Co-Hosts interview NRG-GY018 study PI, Dr. Ramez Eskander on the reported mature results of the study in advanced or recurrent endometrial cancer at ASCO 2026.
• 
  Special Episode with ASTRO’s CEO for ASTRO Advocacy Day 27.04.2026 31m

  The NRG Oncology Podcast discusses the American Society for Radiation Oncology’s (ASTRO) vision and goals, collaborations with cooperative groups such as NRG Oncology, and overcoming obstacles in radiation oncologywith ASTRO’s CEO, Dr. Vivek Kavadi. This is a special episode for ASTRO's 2026 Advocacy Day.
• 
  NRG-GY019 Plenary Presentation at SGO 2026 10.04.2026 17m

  Our co-hosts interview Dr. Amanda Nickles Fader on the recently present results of NRG-GY019.
• 
  NRG-BR009 and the Importance of Cancer Screening 25.03.2026 51m

  Our co-hosts discuss the NRG-BR009 'OFSET' study for premenopausal ER-positive/HER2-negative breast cancer patients that have a high risk of cancer returning with study team members Dr. Shannon Puhalla and Dr. Sandra Swain. Also on this episode, we interview Dr. Haane Massarotti on her own experience facing breast cancer as a young adult.
• 
  Health Policy, Access, and Patient-Reported Outcomes 23.02.2026 37m

  American Medical Association President, Dr. Bobby Mukkamala, discusses how his personal experiences in his cancer journey impact his outlook and goals in his AMA Presidency & Dr. James Yu discusses his experiences using patient-reported outcomes from clinical research to help guide health policy.
• 
  NRG-HN009 Reported at the MHNCS 2026 and NRG-HN010 20.02.2026 37m

  Our co-hosts interview NRG-HN009 PI Dr. Paul Harari on the recently reported initial results of NRG-HN009 at the 2026 Multidisciplary Head and Neck Cancer Symposium. Additionally, this episode discusses NRG-HN010 for HER2-expressing salivary gland cancer with Study PI, Dr. Alan Ho.
• 
  NRG Protocol Operations Management Committee 24.01.2026 22m

  Our co-hosts discuss who the NRG Protocol Operations Management "POM" Committee is and what they are responsible for with outgoing Chair, Dr. Maria Werner-Wasik and incoming Chair, Dr. Alexandra Thomas.
• 
  Sarcoma in NRG and Through the CT3 Foundation with Special Guests 23.01.2026 34m

  In the first half of this episode, our co-hosts interview NRG Oncology Sarcoma Subcommittee Chairs, Dr. Dian Wang and Dr. William Tseng on the priorities and goals of the newer subcommittee within NRG's organization.In the second half, our co-hosts meet with MLB Player Chris Taylor and his wife Mary Taylor, the co-founders of the CT3 Foundation to discuss how sarcoma has touched their lives and fueled their passion to move the needle in sarcoma research. This episode features our first ever guest co-host and former NRG Oncology Group Chair, Dr. Wally Curran.
• 
  The Journal of the American Medical Association (JAMA) with Dr. Bibbins-Domingo 15.12.2025 30m

  JAMA Editor in Cheif, Dr. Kirsten Bibbins-Domingo discusses JAMA and the JAMA Network and the process for selection and publication of manuscripts.
• 
  Smaller Institution Accrual with Dr. Ueno 22.11.2025 18m

  We take a look at the barriers faced by smaller institutions and rural institutions with Dr. Naoto Ueno of the University of Hawaii in a two-episode series on small vs. larger institution challenges.